| Both sides previous revisionPrevious revisionNext revision | Previous revisionBoth sides next revision |
coleman_rotstein [2022/04/19 17:44]
liam [Affiliations] | coleman_rotstein [2022/04/19 19:21] (current)
liam [Affiliations] |
|---|
| He is the former Director of the Division of Infectious Diseases at [[McMaster University]], past Chair and Secretary of the Infectious Diseases Section of the [[Ontario Medical Association]], former Co-chair of the Emerging Infectious Diseases Network, former Past-President of the [[Association of Medical Microbiology and Infectious Disease Canada]], former President of the [[Canadian Infectious Disease Society]], and former Chair of the Clinical Trials Committee of the [[Canadian Infectious Disease Society]]. In addition, he has been elected a fellow of the [[American College of Physicians]] and the [[Infectious Diseases Society of America]]. He is a reviewer for several international journals and was formerly Associate Editor, Review Section, for the [[Canadian Journal of Infectious Diseases and Medical Microbiology]], and for [[Biomed Central Infectious Diseases]]. | He is the former Director of the Division of Infectious Diseases at [[McMaster University]], past Chair and Secretary of the Infectious Diseases Section of the [[Ontario Medical Association]], former Co-chair of the Emerging Infectious Diseases Network, former Past-President of the [[Association of Medical Microbiology and Infectious Disease Canada]], former President of the [[Canadian Infectious Disease Society]], and former Chair of the Clinical Trials Committee of the [[Canadian Infectious Disease Society]]. In addition, he has been elected a fellow of the [[American College of Physicians]] and the [[Infectious Diseases Society of America]]. He is a reviewer for several international journals and was formerly Associate Editor, Review Section, for the [[Canadian Journal of Infectious Diseases and Medical Microbiology]], and for [[Biomed Central Infectious Diseases]]. |
| |
| He is a Professor of Medicine in the Division of Infectious Diseases at the [[University of Toronto]], and an Attending Physician and Director of Oncologic Infectious Diseases of the Immunocompromised Host Infectious Diseases Service at the [[University Health Network]].((//Princess Margaret Cancer Centre Multiple Myeloma Day.// University of Toronto. Retrieved April 18, 2022, from https://archive.ph/HoQqU)) ((//Transplant Research Team.// University Health Network. Retrieved April 19, 2022, from https://web.archive.org/web/20220419154342/https://www.uhn.ca/Transplant/Research/Pages/Transplant_Research_Team.aspx)) | He is a Professor of Medicine in the Division of Infectious Diseases at the [[University of Toronto]], and an Attending Physician and Director of Oncologic Infectious Diseases of the Immunocompromised Host Infectious Diseases Service at the [[University Health Network]].((//Princess Margaret Cancer Centre Multiple Myeloma Day.// University of Toronto. Retrieved April 18, 2022, from https://archive.ph/HoQqU)) ((//Transplant Research Team.// University Health Network. Retrieved April 19, 2022, from https://archive.ph/4Jvnh)) UHN receives funding from a range of [[pharmaceutical companies]] including [[pharmaceutical_companies:Amgen]], [[pharmaceutical_companies:Apotex]], [[pharmaceutical_companies:Astellas]], [[pharmaceutical_companies:AstraZeneca]], [[pharmaceutical_companies:Bayer]], [[pharmaceutical_companies:Boehringer Ingelheim]], [[pharmaceutical_companies:Bristol-Myers Squibb]], [[pharmaceutical_companies:Celgene]], [[pharmaceutical_companies:Eisai]], [[pharmaceutical_companies:Eli Lilly]], [[pharmaceutical_companies:EMD Serono]], [[pharmaceutical_companies:Epizyme]], [[pharmaceutical_companies:GlaxoSmithKline]], [[pharmaceutical_companies:Immunex]], [[pharmaceutical_companies:Janssen]], [[pharmaceutical_companies:Merck]], [[pharmaceutical_companies:Onyx]], [[pharmaceutical_companies:Pfizer]], [[pharmaceutical_companies:Roche]], [[pharmaceutical_companies:Sanofi]], and [[pharmaceutical_companies:Teva]].((//2021 Annual Report.// The Princess Margaret Cancer Foundation. Retrieved April 19, 2022, from https://web.archive.org/web/20211120191604/https://thepmcf.ca/getmedia/9b96649e-83ba-490a-bacc-f961904b94c8/Annual-Report-2021_Digital.pdf)) |
| |
| He is a faculty member for [[Mentoring in IBD]], an annual education program for Canadian gastroenterologists.((//Rotstein, Coleman.// Mentoring in IBD. Retrieved April 19, 2022, from https://archive.ph/IaYBF)) It is currently funded by [[pharmaceutical_companies:AbbVie]], [[pharmaceutical_companies:Amgen]], [[pharmaceutical_companies:Bristol-Myers Squibb]], [[pharmaceutical_companies:Janssen]], [[pharmaceutical_companies:Organon]], [[pharmaceutical_companies:Pfizer]], [[pharmaceutical_companies:Sandoz]], and [[pharmaceutical_companies:Takeda]].((//Sponsors.// Mentoring in IBD. Retrieved April 19, 2022, from https://archive.ph/MMPwq)) | He is a faculty member for [[Mentoring in IBD]], an annual education program for Canadian gastroenterologists.((//Rotstein, Coleman.// Mentoring in IBD. Retrieved April 19, 2022, from https://archive.ph/IaYBF)) It is currently funded by [[pharmaceutical_companies:AbbVie]], [[pharmaceutical_companies:Amgen]], [[pharmaceutical_companies:Bristol-Myers Squibb]], [[pharmaceutical_companies:Janssen]], [[pharmaceutical_companies:Organon]], [[pharmaceutical_companies:Pfizer]], [[pharmaceutical_companies:Sandoz]], and [[pharmaceutical_companies:Takeda]].((//Sponsors.// Mentoring in IBD. Retrieved April 19, 2022, from https://archive.ph/MMPwq)) |
